Justin Fallon, PhD is the Scientific Founder and Director of Tivorsan Pharmaceuticals, discusses Biglycan as an emerging therapy for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).

Biglycan is a small, naturally occurring extracellular matrix protein naturally found in muscle. It is a 37kD polypeptide chain and is a member of the Small Leucine-Rich Repeat Proteoglycan (SLRP) family of proteins. In immature muscle, Biglycan regulates the expression of a key ensemble of cell surface proteins including utrophin, alpha and gamma sarcoglycan, and the NODS complex of nNOS, dystrobrevin and syntrophin.